keyword
MENU ▼
Read by QxMD icon Read
search

Alendronate

keyword
https://www.readbyqxmd.com/read/29649498/the-wakefulness-promoting-drug-modafinil-causes-adenosine-receptor-mediated-upregulation-of-receptor-activator-of-nuclear-factor-%C3%AE%C2%BAb-ligand-in-osteoblasts-negative-impact-of-the-drug-on-peak-bone-accrual-in-rats
#1
Shyamsundar Pal China, Subhashis Pal, Sourav Chattopadhyay, Konica Porwal, Monika Mittal, Sabyasachi Sanyal, Naibedya Chattopadhyay
Modafinil is primarily prescribed for treatment of narcolepsy and other sleep-associated disorders. However, its off-prescription use as a cognition enhancer increased considerably, specially among youths. Given its increasing use in young adults the effect of modafinil on peak bone accrual is an important issue but has never been investigated. Modafinil treatment to young male rats caused trabecular and cortical bone loss in tibia and femur, and reduction in biomechanical strength. Co-treatment of modafinil with alendronate (a drug that suppresses bone resorption) reversed the trabecular bone loss but failed to prevent cortical loss...
April 9, 2018: Toxicology and Applied Pharmacology
https://www.readbyqxmd.com/read/29627514/combined-effects-of-photobiomodulation-and-alendronate-on-viability-of-osteoporotic-bone-marrow-derived-mesenchymal-stem-cells
#2
Somaye Fallahnezhad, Abdollah Amini, Behnam Hajihossainlou, Sufan Chien, Sara Dadras, Fatemehalsadat Rezaei, Mohammad Bayat
Osteoporotic bone marrow mesenchymal stem cells (BMMSCs) are involved in the pathogenesis of osteoporosis (OP). Photobiomodulation (PBM) has positive effects on healthy BMMSCs. The goal of current experiment was to evaluate the combined influence of photobiomodulation PBM and alendronate (ALN) incubation on ovariectomized induced osteoporosis(OVX)- BMMSC viability in vitro. 15 female adult Wistar rats were distributed into the 2 groups: (1) 3 healthy (sham)control rats, (2) 12 OVX- rats. All OVX rats underwent ovariectomy...
March 22, 2018: Journal of Photochemistry and Photobiology. B, Biology
https://www.readbyqxmd.com/read/29627155/alendronate-and-fti-277-combination-as-a-possible-therapeutic-approach-for-hepatocellular-carcinoma-an-in-vitro-study
#3
Amber Ilyas, Zehra Hashim, Iffat Saeed Channa, Shamshad Zarina
BACKGROUND: An important product of mevalonate pathway is downstream synthesis of isoprenoid units that has long been implicated in development and progression of tumor. It has been speculated that inhibition of protein prenylation might be therapeutically beneficial. The objective of current study was to evaluate antitumor potential of a novel therapeutic combination of mevalonate pathway inhibitors, FTI-277 and alendronate. We also examined differentially expressed proteins in response to treatment using proteomics approach...
March 24, 2018: Hepatobiliary & Pancreatic Diseases International: HBPD INT
https://www.readbyqxmd.com/read/29626715/targeting-therapeutics-to-bone-by-conjugation-with-bisphosphonates
#4
REVIEW
Robert N Young, Marc D Grynpas
Bisphosphonates target and bind avidly to the mineral (hydroxyapatite) found in bone. This targeting ability has been exploited to design and prepare bisphosphonate conjugate prodrugs to deliver a wide variety of drug molecules selectively to bones. It is important that conjugates be stable in the blood stream and that conjugate that is not taken up by bone is eliminated rapidly. The prodrugs should release active drug at a rate appropriate so as to provide efficacy. Radiolabelling is the best method to quantify and evaluate pharmacokinetics, tissue distribution, bone uptake and release of the active drug(s)...
April 4, 2018: Current Opinion in Pharmacology
https://www.readbyqxmd.com/read/29625341/medications-as-a-potential-source-of-exposure-to-parabens-in-the-u-s-population
#5
Laura E Dodge, Jee Woong Choi, Katherine E Kelley, Sonia Herńandez-D Iaz, Russ Hauser
INTRODUCTION: Use of paraben-containing medications has been shown to be associated with urinary paraben concentrations among couples undergoing fertility treatment, but it is unknown whether this association is also present among the general population. METHODS: A list of prescription medications of interest was developed based on their likelihood of containing parabens and the ability to identify users in the National Health and Nutrition Examination Survey (NHANES); alendronate, escitalopram oxalate, fluoxetine, and olanzapine were chosen...
April 3, 2018: Environmental Research
https://www.readbyqxmd.com/read/29616561/denosumab-a-unique-perspective-on-adherence-and-cost-effectiveness-compared-with-oral-bisphosphonates-in-osteoporosis-patients
#6
Paige Morizio, Jena I Burkhart, Sachiko Ozawa
OBJECTIVE: To assess the cost-effectiveness as well as adherence and patient preference for denosumab compared with oral bisphosphonates for the treatment of osteoporosis. DATA SOURCES: Two comprehensive PubMed literature searches (from data inception to December 2017) were performed. The first search included the terms osteoporosis, denosumab, bisphosphonate, and adherence or persistence or compliance or preference. The search terms osteoporosis, denosumab, cost, and effectiveness were used in the second literature search...
April 1, 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29615391/differences-in-rates-of-switchbacks-after-switching-from-branded-to-authorized-generic-and-branded-to-generic-drug-products-cohort-study
#7
Rishi J Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F Khan, Joyce Lii, James R Rogers, Sarah K Dutcher, Saeid Raofi, Justin Bohn, John Connolly, Michael A Fischer, Aaron S Kesselheim, Joshua J Gagne
OBJECTIVES: To compare rates of switchbacks to branded drug products for patients switched from branded to authorized generic drug products, which have the same active ingredients, appearance, and excipients as the branded product, with patients switched from branded to generic drug products, which have the same active ingredients as the branded product but may differ in appearance and excipients. DESIGN: Observational cohort study. SETTING: Private (a large commercial health plan) and public (Medicaid) insurance programs in the US...
April 3, 2018: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/29607978/the-efficacy-of-minodronate-in-the-treatment-of-glucocorticoid-induced-osteoporosis
#8
Eriko Hasegawa, Satoshi Ito, Chinatsu Takai, Daisuke Kobayashi, Yumi Nomura, Hiroshi Otani, Asami Abe, Hajime Ishikawa, Akira Murasawa, Ichiei Narita, Kiyoshi Nakazono
Objective To investigate the efficacy of minodronate in the treatment of glucocorticoid-induced osteoporosis (GIO). Methods The study population included patients in whom the administration of minodronate (50 mg, once every 4 weeks) had been newly started for the treatment of GIO in Niigata Rheumatic Center from 2012 to 2015. Patients who were bisphosphonate-naïve and those who switched from other bisphosphonates were classified into the naïve and switch groups, respectively. The changes in the bone mineral density (BMD) and bone metabolic markers after one year of minodronate treatment were retrospectively evaluated...
March 30, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29603071/serum-homocysteine-levels-are-affected-by-renal-function-during-a-3-year-period-of-minodronate-therapy-in-female-osteoporotic-patients
#9
Tsuyoshi Ohishi, Tomotada Fujita, Daisuke Suzuki, Tatsuya Nishida, Mitsuru Asukai, Yukihiro Matsuyama
Serum homocysteine is a possible marker to indicate bone quality. However, it is not clear whether changes are seen in serum homocysteine levels with long-term bisphosphonate therapy. We aimed to investigate the factors affecting serum homocysteine levels during a 3-year period of monthly minodronate therapy in osteoporotic women, and to examine if the serum homocysteine levels could reflect some aspects of bone metabolism. The study included 43 patients (age 72.3 ± 7.0 years) undergoing treatment for osteoporosis for the first time (New group) and 35 patients (age 74...
March 30, 2018: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/29600563/alendronate-induces-osteoclast-precursor-apoptosis-via-peroxisomal-dysfunction-mediated-er-stress
#10
Ning Ding, Chuan Liu, Li Yao, Yun Bai, Peng Cheng, Zhilin Li, Keyu Luo, Tieniu Mei, Jianhua Li, Junchao Xing, Xiaoliang Gao, Qinyu Ma, Jianzhong Xu, Fei Luo, Ce Dou
Nitrogen-containing bisphosphonates including alendronate (ALN) are the current first line antiresorptive drug in treating osteoporosis. In our study, we found that ALN administration impaired the secretion of platelet derived growth factor-BB (PDGF-BB), the most important angiogenic cytokines produced by preosteoclast (POC), in both sham and ovariectomized (OVX) mice. To further understand this phenomenon, we induced bone marrow macrophages (BMMs) to POCs in vitro and detected the effects of ALN particularly in POCs...
March 30, 2018: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29594456/combined-pharmacotherapy-for-osteonecrosis-of-the-femoral-head-after-severe-acute-respiratory-syndrome-and-interstitial-pneumonia-two-and-a-half-to-fourteen-year-follow-up
#11
Weiguo Wang, Nianfei Zhang, Wanshou Guo, Fuqiang Gao
PURPOSE: The purpose of this study was to retrospectively analyze the clinical, functional, and radiological outcomes of combined pharmacotherapy to ONFH after high-dose corticosteroid therapy. METHOD: From August 2003 to June 2015, five patients (ten hips) of ONFH in ARCO stage I, after SARS and Interstitial pneumonia, were treated by combined pharmacotherapy. Lipo-prostaglandin E1 10 μg iv Bid × 28 days, enoxaparin 6000 iu H QD × 12 weeks, alendronate sodium tablet 10 mg QD × 1 year...
March 28, 2018: International Orthopaedics
https://www.readbyqxmd.com/read/29578126/efficacy-and-safety-of-different-bisphosphonates-for-bone-loss-prevention-in-kidney-transplant-recipients-a-network-meta-analysis-of-randomized-controlled-trials
#12
Yan Yang, Shi Qiu, Xi Tang, Xin-Rui Li, Ling-Hui Deng, Qiang Wei, Ping Fu
Background: Mineral and bone disorder is one of the severe complications in kidney transplant recipients (KTRs). Previous studies showed that bisphosphonates had favorable effects on bone mineral density (BMD). We sought to compare different bisphosphonate regimens and rank their strategies. Methods: We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) up to April 01, 2017, for randomized controlled trials (RCTs) comparing bisphosphonate treatments in adult KTRs...
April 5, 2018: Chinese Medical Journal
https://www.readbyqxmd.com/read/29564555/treatment-patterns-in-patients-with-osteoporosis-at-high-risk-of-fracture-in-japan-retrospective-chart-review
#13
Saeko Fujiwara, Akimitsu Miyauchi, Etsuro Hamaya, Rebecca Jayne Nicholls, Adele Weston, Santwona Baidya, Lionel Pinto, Rich Barron, Junichi Takada
Osteoporosis (OP) causes reduced bone strength and increases risk of fractures. Medical records from specialist clinics in Japan of postmenopausal women with OP and high risk of fracture were analysed. Majority of patients were treated for OP as recommended and were prescribed OP medications soon after high-risk OP diagnosis. PURPOSE: The incidence of osteoporosis (OP) in Japan is predicted to increase significantly in coming decades. Resultant osteoporotic fractures are a significant contributor of economic and social burden among elderly osteoporosis patients...
March 22, 2018: Archives of Osteoporosis
https://www.readbyqxmd.com/read/29545029/the-effects-of-three-modified-hank-s-balanced-salt-solutions-on-root-resorption-of-late-replanted-teeth-a-pilot-study
#14
Hanyu Qian, Yunpeng Ding, Yangou Wu, Shengjiao Li
PURPOSE: The purpose of this study was to evaluate the effects of replanted rats' teeth that had been soaked in one of three modified Hank's balanced salt solutions (HBSSs) before replantation and after extended extra-oral dry time. MATERIALS AND METHODS: Maxillary right incisors were extracted from 55 Wistar rats and kept dry for 30 or 60 min (n = 5 each). Afterwards, the pulp was extirpated and both the papilla and enamel organ were removed with a scalpel. Each group of teeth was soaked in one of three modified HBSSs or HBSS alone...
February 21, 2018: Journal of Cranio-maxillo-facial Surgery
https://www.readbyqxmd.com/read/29543887/the-effects-of-denosumab-and-alendronate-on-glucocorticoid-induced-osteoporosis-in-patients-with-glomerular-disease-a-randomized-controlled-trial
#15
Ken Iseri, Masayuki Iyoda, Makoto Watanabe, Kei Matsumoto, Daisuke Sanada, Takashi Inoue, Shohei Tachibana, Takanori Shibata
INTRODUCTION: The clinical utility of denosumab for the treatment of glucocorticoid-induced osteoporosis (GIOP) has yet to be established. This study aimed to compare the effects of denosumab on bone mineral density (BMD) and bone turnover markers to those of alendronate in patients with GIOP. METHODS: A prospective, single-center study of 32 patients (18 men; median age, 66.0 years) with glomerular disease receiving prednisolone (PSL) who were diagnosed as having GIOP and had not received bisphosphonates before was conducted...
2018: PloS One
https://www.readbyqxmd.com/read/29531334/effect-of-high-frequency-loading-and-parathyroid-hormone-administration-on-peri-implant-bone-healing-and-osseointegration
#16
Aya Shibamoto, Toru Ogawa, Joke Duyck, Katleen Vandamme, Ignace Naert, Keiichi Sasaki
The objective of this study is to examine the effect of low-magnitude, high-frequency (LMHF) loading, and anti-osteoporosis medications such as parathyroid hormone (PTH) and bisphosphonates on peri-implant bone healing in an osteoporosis model, and to assess their combined effects on these processes. Thirteen-week-old ovariectomized rats (n = 44) were divided into three groups: PTH, alendronate, and saline. After 3 weeks of drug administration, titanium implants were inserted into the tibiae. Each group was subdivided into two groups: with or without LMHF loading via whole-body vibration (50 Hz at 0...
March 13, 2018: International Journal of Oral Science
https://www.readbyqxmd.com/read/29525970/effects-of-discontinuing-oral-bisphosphonate-treatments-for-postmenopausal-osteoporosis-on-bone-turnover-markers-and-bone-density
#17
K E Naylor, M Bradburn, M A Paggiosi, F Gossiel, N F A Peel, E V McCloskey, J S Walsh, R Eastell
The antiresorptive potency varies between different bisphosphonates. We investigated the effect of stopping oral bisphosphonate treatment for postmenopausal osteoporosis (ibandronate, alendronate, risedronate) on BTMs and BMD. After stopping treatment, all three groups showed an increase in BTMs and a decrease in hip BMD; however, none returned to pre-treatment baseline values. INTRODUCTION: Bisphosphonates (BPs) continue to suppress bone turnover markers (BTMs) after treatment has stopped, leading to the suggestion that a pause in treatment could be considered for low-risk patients...
March 10, 2018: Osteoporosis International
https://www.readbyqxmd.com/read/29517866/-subtrochanteric-pathological-fracture-on-bisphosphonates
#18
P Y Mathonet, S Willems, J F Ciornohac
Bisphosphonates have frequently shown their efficacy in the treatment of osteoporosis, including ibandronate and alendronate. But more and more mention is made in the literature of patients taking a long-term bisphosphonate and undergoing an atypical fracture associated with this therapy. These complications are most often femoral fractures in the proximal part of the femoral diaphysis. We report the case of a 73-year-old patient who had a subtrochanteric pathological fracture after a prolonged intake of alendronate followed by ibandronate...
February 2018: Revue Médicale de Liège
https://www.readbyqxmd.com/read/29512306/preventing-muscle-wasting-by-osteoporosis-drug-alendronate-in-vitro-and-in-myopathy-models-via-sirtuin-3-down-regulation
#19
Hsien-Chun Chiu, Chen-Yuan Chiu, Rong-Sen Yang, Ding-Cheng Chan, Shing-Hwa Liu, Chih-Kang Chiang
BACKGROUND: A global consensus on the loss of skeletal muscle mass and function in humans refers as sarcopenia and cachexia including diabetes, obesity, renal failure, and osteoporosis. Despite a current improvement of sarcopenia or cachexia with exercise training and supportive therapies, alternative and specific managements are needed to discover for whom are unable or unwilling to embark on these treatments. Alendronate is a widely used drug for osteoporosis in the elderly and postmenopausal women...
March 6, 2018: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/29511371/bisphosphonate-modulation-of-the-gene-expression-of-different-markers-involved-in-osteoblast-physiology-possible-implications-in-bisphosphonate-related-osteonecrosis-of-the-jaw
#20
Francisco Javier Manzano-Moreno, Javier Ramos-Torrecillas, Lucia Melguizo-Rodríguez, Rebeca Illescas-Montes, Concepción Ruiz, Olga García-Martínez
The aim of the present study was to elucidate the role of osteoblasts in bisphosphonates-related osteonecrosis of the jaw (BRONJ). The specific objective was to evaluate the effect on osteoblasts of two nitrogen-containing BPs (zoledronate and alendronate) and one non-nitrogen-containing BP (clodronate) by analyzing modulations in their expression of genes essential for osteoblast physiology. Real-time polymerase chain reaction (RT-PCR) was used to study the effects of zoledronate, alendronate, and clodronate at doses of 10-5 , 10-7 , or 10-9 M on the expression of Runx-2, OSX, ALP, OSC, OPG, RANKL, Col-I, BMP-2, BMP-7, TGF-β1, VEGF, TGF-βR1, TGF-βR2, and TGF-βR3 by primary human osteoblasts (HOBs) and MG-63 osteosarcoma cells...
2018: International Journal of Medical Sciences
keyword
keyword
27344
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"